Search results
Mitigating Muscle Loss Becoming More Vital, Global Cancer Cachexia Market Projected to Reach $3.3...
Morningstar· 8 hours agoFN Media Group News Commentary - There is much activity in finding better ways in mitigating muscle loss for the cancer patients… many clinical studies are looking for elite performance nutritional ...
Moderna beats estimates in Q1 2024, targets RSV vaccine launch in fall By Investing.com
Investing.com· 6 days agoModerna Inc. (NASDAQ:MRNA) reported first-quarter earnings and revenue that came ahead of analyst...
Moderna Shares Jump After Better-Than-Expected Sales
The Wall Street Journal· 6 days agoModerna shares shot up about 7% Thursday after reporting better-than-expected quarterly sales and signaling confidence in a sales pickup later this year....
'Fighting for Approval': Barriers to Needed Medications
Medscape· 7 days agoTherapies such as growth hormones and puberty blockers often face shortages, leaving pediatric...
Moderna to seek parity for RSV shot (NASDAQ:MRNA)
Seeking Alpha· 6 days agoModerna (MRNA) stock gains as the company highlights its upcoming RSV shot, expecting the U.S. regulators to endorse it on par with rival products. Read more here.
Moderna (MRNA) Q1 2024 Earnings Call Transcript
Motley Fool via Yahoo Finance· 6 days agos first-quarter 2024 financial results and business updates. You can access the press release issued this morning as well as the slides that we'll be...
Tech Bytes: Moderna partners with OpenAI to expedite drug development processes
Proactive Investors· 2 days agoWith a valuation of US$47 billion (~A$71 billion), Moderna aims to leverage AI to automate functions...
Merck Reports Progress On The Cancer Front As It Prepares For Keytruda Patent Expiration
Benzinga via Yahoo Finance· 6 days agoAfter topping expectations with first quarter revenue and adjusted earnings last week, Merck & Co...
Moderna Reports Smaller Than Expected Q1 Loss, Prepares For RSV Vaccine And Spikevax 2024-2025...
Benzinga via Yahoo Finance· 6 days agoThursday, Moderna Inc (NASDAQ:MRNA) reported a first-quarter EPS loss of $(3.07), down from an...
Moderna Reports First Quarter 2024 Financial Results and Provides Business Updates
Morningstar· 6 days agoReports first quarter revenues of $167 million, GAAP net loss of $1.2 billion and GAAP diluted EPS of $(3.07)Prepares for launches of RSV vaccine and Spikevax® 2024-2025 formula; reaffirms 2024 ...